Associatedwith a specific pattern of cerebralwhite matter injury in individuals with mild cognitive impairment enrolled to the adni study

of controls (n1⁄439), otherwise they were classified as Ab(n1⁄456). We selected age and cognitively matched subjects with two years follow up data. Results: At baseline, Ab+MCI and Ab-MCI had comparable MMSE, CDR and ADAS-Cog11 scores; Ab+MCI had higher prevalence of ApoEε4 carriers (66.7% vs 28.6%). There were no significant differences in brain glucose metabolism between the two groups in all the predefined regions, as well as in hippocampal volume. At 2-years follow-up, Ab+MCI had a significant reduction in ADAS-Cog11 scores, in hippocampal volume and glucose uptake compared to baseline. However, Ab-MCI only showed a significant decrease in hippocampal volume compared to baseline. Regression analysis has shown that cognitive decline measured by ADAS-Cog11 was associated with APOEε4 carrier status in Ab+MCI, but not with age and gender; in Ab-MCI, ADAS-Cog11 change was associated with baseline hippocampal FDG uptake. Conclusions: This data suggests that ApoE4 is a significant predictor of cognitive decline in amyloid positive MCI subjects, while hippocampal glucose metabolism is a better predictor of cognitive deterioration in amyloid negative MCI subjects. This will have significant impact on the selection of biomarkers to evaluate therapeutic intervention studies.